These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26851154)

  • 21. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state.
    Rathi S; Chavan RB; Shastri NR
    Drug Deliv Transl Res; 2020 Feb; 10(1):70-82. PubMed ID: 31407270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of co-crystals in pharmaceutical design.
    Steed JW
    Trends Pharmacol Sci; 2013 Mar; 34(3):185-93. PubMed ID: 23347591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards effective solid form screening.
    Allesø M; Tian F; Cornett C; Rantanen J
    J Pharm Sci; 2010 Sep; 99(9):3711-8. PubMed ID: 19798763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphic phase transitions: Macroscopic theory and molecular simulation.
    Anwar J; Zahn D
    Adv Drug Deliv Rev; 2017 Aug; 117():47-70. PubMed ID: 28939378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging role of primary heterogeneous nucleation in pharmaceutical crystallization.
    Thakore SD; Sood A; Bansal AK
    Drug Dev Res; 2020 Feb; 81(1):3-22. PubMed ID: 31800139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.
    Sood J; Sapra B; Bhandari S; Jindal M; Tiwary AK
    Ther Deliv; 2014 Oct; 5(10):1123-42. PubMed ID: 25418270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New forms of old drugs: improving without changing.
    Domingos S; André V; Quaresma S; Martins IC; Minas da Piedade MF; Duarte MT
    J Pharm Pharmacol; 2015 Jun; 67(6):830-46. PubMed ID: 25648101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An industrial perspective on co-crystals: Screening, identification and development of the less utilised solid form in drug discovery and development.
    Kendall T; Stratford S; Patterson AR; Lunt RA; Cruickshank D; Bonnaud T; Scott CD
    Prog Med Chem; 2021; 60():345-442. PubMed ID: 34147205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization and Quality Control of Pharmaceutical Cocrystals.
    Izutsu KI; Koide T; Takata N; Ikeda Y; Ono M; Inoue M; Fukami T; Yonemochi E
    Chem Pharm Bull (Tokyo); 2016 Oct; 64(10):1421-1430. PubMed ID: 27319284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computed crystal energy landscapes for understanding and predicting organic crystal structures and polymorphism.
    Price SS
    Acc Chem Res; 2009 Jan; 42(1):117-26. PubMed ID: 18925751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supramolecular Metal-Phenolic Gels for the Crystallization of Active Pharmaceutical Ingredients.
    Rahim MA; Hata Y; Björnmalm M; Ju Y; Caruso F
    Small; 2018 Jun; 14(26):e1801202. PubMed ID: 29808530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for cocrystallization tendency: the role of intermolecular interactions.
    He G; Jacob C; Guo L; Chow PS; Tan RB
    J Phys Chem B; 2008 Aug; 112(32):9890-5. PubMed ID: 18646803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design.
    Berry DJ; Steed JW
    Adv Drug Deliv Rev; 2017 Aug; 117():3-24. PubMed ID: 28344021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of solid polymer dispersions of active pharmaceutical ingredients by 19F MAS NMR and factor analysis.
    Urbanova M; Brus J; Sedenkova I; Policianova O; Kobera L
    Spectrochim Acta A Mol Biomol Spectrosc; 2013 Jan; 100():59-66. PubMed ID: 22421443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.